CLAIM CARD
The evidence base reveals notable tensions regarding context-dependency. By contrast, the positive cardioprotective signal from the anthracycline-exposed SAFE cohort (Meattini 2025; Bene 2025) stands in disagreement with the null or mixed findings from the TAVI (AmatSantos 2024) and post-myocardial infarction (Wang 2023) populations. These disagreements suggest that any potential geroprotective or cardioprotective benefit of ACE inhibitors is highly specific to the clinical context and underlying pathophysiology, rather than a generalizable effect.
Evidence grade: exploratory
Contradiction status: none
Publication: 9ab2e887-2e5b-429a-8d89-fd6d7813a028
Provenance: Derivation Web chain
Citation Support
source_1Lin 2026source_2Din 2026source_3Spiegeleer 2025source_4Shen 2025source_5Bene 2025